ID   K562/Vin
AC   CVCL_5145
SY   K562/VCR; K562 H-1; H-1
DR   CLO; CLO_0050125
DR   ChEMBL-Cells; CHEMBL4295433
DR   ChEMBL-Targets; CHEMBL4296450
DR   PubChem_Cell_line; CVCL_5145
DR   RCB; RCB2111
DR   TKG; TKG 0212
DR   Wikidata; Q54899418
RX   PubMed=6580255;
RX   PubMed=6684716;
CC   Population: Caucasian.
CC   Doubling time: 24.1 +- 1.8 hours (PubMed=6580255).
CC   Selected for resistance to: ChEBI; CHEBI:28445; Vincristine (VCR).
CC   Sequence variation: Gene fusion; HGNC; 76; ABL1 + HGNC; 1014; BCR; Name(s)=BCR-ABL1, BCR-ABL (from parent cell line).
CC   Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Gln136fs*13 (c.406_407insC); Zygosity=Homozygous (from parent cell line).
CC   Derived from site: In situ; Pleural effusion; UBERON=UBERON_0000175.
ST   Source(s): RCB; TKG
ST   Amelogenin: X
ST   CSF1PO: 9,10
ST   D13S317: 8
ST   D16S539: 11,12
ST   D5S818: 11,12
ST   D7S820: 9,11
ST   TH01: 9.3
ST   TPOX: 8,9
ST   vWA: 16
DI   NCIt; C9110; Blast phase chronic myelogenous leukemia, BCR-ABL1 positive
DI   ORDO; Orphanet_521; Chronic myeloid leukemia
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
HI   CVCL_0004 ! K-562
SX   Female
AG   53Y
CA   Cancer cell line
DT   Created: 04-04-12; Last updated: 29-06-23; Version: 22
//
RX   PubMed=6580255; DOI=10.20772/cancersci1959.74.5_751;
RA   Tsuruo T., Iida H., Ohkochi E., Tsukagoshi S., Sakurai Y.;
RT   "Establishment and properties of vincristine-resistant human
RT   myelogenous leukemia K562.";
RL   Gann 74:751-758(1983).
//
RX   PubMed=6684716; DOI=10.1016/0145-2126(83)90043-7;
RA   Okabe-Kado J., Hayashi M., Honma Y., Hozumi M., Tsuruo T.;
RT   "Effects of inducers of erythroid differentiation of human leukemia
RT   K562 cells on vincristine-resistant K562/VCR cells.";
RL   Leuk. Res. 7:481-485(1983).
//